US FDA Has Soured On Abuse Deterrent Labeling Even Outside Of Opioids, Stimulant Docs Suggest

 
• By Sarah Karlin-Smith
  
Steep grades and curves, road sign, dangerous road
Arbor faces a difficult road to advisory committee and FDA sign-off for its reformulated ADHD treatment • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers